The vacancy against the AstraZeneca / Oxford covid-19 is easy and easy to deal with, but controversial accumulation is taking place in relation to the secondary effects.
These are some of its main features:
– “Vector viral” –
This vacancy was unveiled by Oxford University investigators in collaboration with British pharmaceutical giant AstraZeneca.
It is a “viral vector” vaccine: it is just like the base of another virus (a chimpanzee adenovirus) which is debilitated and genetically modified to prevent the coronavirus from reproducing in the human body.
The form in which the genetic material is introduced into the cells, ordinances that attack SARS-CoV-2, has been classified as “Trojan horse”.
– Practical and unequal –
The AstraZeneca / Oxford car has the bargain price (2.5 euros or 3 dollars per dose, with variations depending on local production costs). AstraZeneca has compromised to become a beneficiary.
It is also easy to increase: you can preserve the temperature of a refrigerator, between 2ºC and 8ºC, differentiating the vacancies of Moderna and Pfizer / BioNTech, which can only be increased and large space and very low temperatures.
A large scale evacuation is facilitated.
This pharmacy, in addition, is distributed through the Covax program to the most disadvantaged countries.
– Questions about secondary effects –
The suspects appear on the possible serious secondary effects, although common, through the detection of atypical thrombosis cases in patients evacuated with AstraZeneca.
He recorded decades of cases, some of the cases he derived in bankruptcy.
The United Kingdom reported 30 cases and deaths, up to a total of 18.1 million administered doses up to 24 March. No similar observations have been made during the Pfizer / BioNTech drug dose application.
According to the European Medicines Agency (EMA), “no causality relationship has been tested, but it is possible”, and the benefits of immunization against coronavirus are higher than the risks.
As a precaution, various countries have decided not to administer this vaccine on the eve of the last edition, such as Germany and the Netherlands (60 years), France and Canada (55 years), and Sweden and Finland (65 years).
For its part, AstraZeneca assured in March that “it has no proof of a serious aggravation”.
– Confusion about its efficiency –
According to the British laboratory, it has a 70% drug efficiency (up to 90% from Pfizer / BioNTech and Modern), validated by The Lancet Scientific Review.
In the first published results, procedures of clinical trials prevailing in its treatment, apparent variations of efficacy, all different dose administered by mistake, what the doubt and provocation proves, leading the company to carry out additional studies.
Its 65-year-old mayor’s capacity was also spent in Europe due to a lack of data, up to date with new information, extracts from holiday camps in the most advanced countries in this area, with respect for them.
In the United States, the regulator of drugs criticized the pharmaceutical group for having summarized data “obsolete” in its clinical trials. For this, it reduces its efficiency to 76% in the case of cases, up to 79%.
British studies conducted under real conditions, in Scotland and England, will provide important protection for hospitalization.
– Back in the entrances –
According to AstraZeneca, in March, the vaccine facility was approved in more than 70 countries. The United Kingdom was the first to authorize and collect 100 million doses.
The retreats in the remnants of the countries of the European Union provoke arduous queues, and the laboratory is located in the United Kingdom of the Promised Existence. Due to the lack of creditors, the European Commission decided to control the export of antique vehicles to impede entry into other countries.
This situation is causing tensions between Brussels and London, but it is up to them to compromise and resolve the mediation litigation.